Skip to main content
. 2023 Mar 7;8:104. doi: 10.1038/s41392-023-01365-z

Table 3.

Phagocytosis checkpoint targeting drugs in clinical trial (registered in US) and investigational new drug (IND) stage

Company Name (sponsor) Drug name main component Target Disease Clinical phase Combination drug single-drug therapy or combination therapy National Clinical Traial Number (NCT NO.)
Akeso AK117 Monoclonal Antibody CD47 MDS Phase 1/2 Azacitidine combination therapy NCT04900350
AML Phase 1/2 Azacitidine combination therapy NCT04980885
Advanced Malignancies Phase 1/2 AK112/Chemotherapy combination therapy NCT05214482
Advanced Malignancies Phase 1/2 AK112/Carboplatin/Cisplatin/5-Fluorouracil combination therapy NCT05229497
Advanced Malignancies Phase 1/2

AK104/Capecitabine tablets/Oxaliplatin/

Cisplatin/Paclitaxel/Irinotecan/Docetaxel/5-FU

 combination therapy NCT05235542
Neoplasms Malignant Phase 1 single-drug therapy

NCT04728334/

NCT04349969
ALX Oncology ALX148/evorpacept Fusion protein CD47 Gastric Cancer Phase 2/3 Trastuzumab/Ramucirumab/Paclitaxel combination therapy NCT05002127
NHL Phase 1/2 Lenalidomide/Biological: Rituximab combination therapy NCT05025800
MDS Phase 1/2 Azacitidine combination therapy NCT04417517
AML Phase 1/2 Venetoclax/Drug: Azacitidine combination therapy NCT04755244
Head and Neck Cancer Phase 2 Pembrolizumab/Cisplatin/Carboplatin; 5FU combination therapy NCT04675333
Head and Neck Cancer Phase 2 Pembrolizumab combination therapy NCT04675294
MSS Metastatic Colorectal Cancer Phase 2 Cetuximab/Drug: Pembrolizumab combination therapy NCT05167409
Solid Tumor/NHL Phase 1

Pembrolizumab/Trastuzumab/Rituximab/

Ramucirumab + Paclitaxel/5-FU + Cisplatin

 combination therapy NCT03013218
Arch Oncology AO-176 Monoclonal Antibody CD47 Solid Tumor Phase 1/2 Paclitaxel/Pembrolizumab combination therapy NCT03834948
Multiple Myeloma Phase 1/2 Dex/Dex + Bort combination therapy NCT04445701
Bio-Thera Solutions BAT7104 bispecific antibody CD47/PD-L1 Solid Tumor Phase 1 single-drug therapy NCT05200013
Chia Tai Tianqing TQB2928 Monoclonal Antibody CD47 Advanced Malignancies Phase 1 single-drug therapy NCT05192512
Elpiscience ES004 Monoclonal antibody SIRPα Malignant tumor IND /
EpicentRx RRx-001 Small molecular CD47/SIRPα axis Small Cell Lung Cancer Phase 3 Cisplatin/carboplatin plus etoposide combination therapy NCT03699956
Colorectal Neoplasms Phase 2 Regorafenib/Irinotecan combination therapy NCT02096354
Solid Tumor Phase 2

Cisplatin/Cisplatin/Etoposide/Carboplatin/

Irinotecan/Vinorelbine/Doxil/Gemcitabine/

Taxane/Paclitaxel/ Nab-Paclitaxel/Pemetrexed

 combination therapy NCT02489903
Oral Mucositis Phase 2 Cisplatin combination therapy NCT03515538
Cholangiocarcinoma Phase 2 Gemcitabine and cisplatin combination therapy

NCT02452970;

erminated (Resensitization or clinical benefit was not observed)
Brain Metastases Phase 1 WBRT combination therapy NCT02215512
Solid Tumor/Lymphoma Phase 1 single-drug therapy NCT02096341
Progressive Malignant Solid and Central Nervous System Tumors (PIRATE) Phase 1 Temozolomide/ Irinotecan combination therapy NCT04525014
Metastatic or Advanced Cancer Phase 1 Irinotecan combination therapy NCT02801097
Solid Tumor/Lymphoma Phase 1 Nivolumab combination therapy NCT02518958
Glioblastoma and Anaplastic Gliomas Phase 1 Temozolomide/TMZ combination therapy NCT02871843
Solid Tumor/Lymphoma Phase 1 single-drug therapy NCT01359982
Conjupro CPO107 bispecific antibody SIRPα/CD20 CD20 Positive NHL Phase 1/2 single-drug therapy NCT04853329
GeneScience Gentulizumab Monoclonal Antibody CD47 Solid Tumor/NHL Phase 1 single-drug therapy NCT05221385
CD47 AML/MDS Phase 1 single-drug therapy NCT05263271
Gilead Sciences Magrolimab Monoclonal Antibody CD47 HL Phase 2 Drug: Pembrolizumab/Procedure: PET/CT combination therapy NCT04788043
MDS/AML Phase 1/2 Drug: Sabatolimab/Drug: Azacitidine combination therapy NCT05367401
Solid Tumor Phase 1 single-drug therapy NCT02216409
Hematological Malignancies Phase 1 Drug: Azacitidine combination therapy NCT03248479
Lymphoma Phase 1 Drug: Obinutuzumab/Drug: Venetoclax combination therapy NCT04599634
Hengrui Pharmaceuticals SHR-1603 Monoclonal Antibody CD47 Nasopharyngeal Carcinoma Phase1

single and combined withGemcitabine/

Cisplatin/Albumin Paclitaxel

single-drug therapy and

combination therapy

 NCT04282070
Solid Tumor Phase 1 single-drug therapy NCT03710265
I-MAB TJC4 monoclonal antibody CD47 AML/MDS Phase1 Lemzoparlimab/Azacitidine/Venetoclax combination therapy NCT04912063
Multiple Myeloma Phase1

Lemzoparlimab/Dexamethasone/

Carfilzomib/Pomalidomide/Daratumumab

 combination therapy NCT04895410

TJ-011133

(Lemzoparlimab)

 Solid Tumor Phase 1/2 toripalimab combination therapy NCT05148533
AML/MDS Phase 1/2 single-drug therapy NCT04202003
MDS Phase 1 Azacitidine/Venetoclax combination therapy NCT04912063
Multiple Myeloma Phase 1

Single or combined with examethasone/

Carfilzomib/Pomalidomide/Daratumumab

single-drug therapy and

combination therapy

 NCT04895410
Solid Tumor/Lymphoma Phase 1 Pembrolizumab/Rituximab combination therapy NCT03934814
MDS Phase 1 Azacitidine/Venetoclax combination therapy NCT04912063
ImmuneOncia IMC-002 Monoclonal Antibody CD47 Advanced Malignancies Phase 1 single-drug therapy

NCT05276310/

NCT04306224
ImmuneOnco Biopharma IMM-01 Fusion protein CD47 AML/MDS Phase 1/2 Azacitidine combination therapy NCT05140811
IMM-2505 bispecific antibody PD-L1/CD47 Advanced Malignancies IND single-drug therapy IND
IMM2902 bispecific antibody CD47/SIRPα HER2-expressing Advanced Solid Tumor Phase 1 single-drug therapy NCT05076591
IMM0306 bispecific antibody CD47/CD20 B-NHL Phase 1 single-drug therapy NCT04746131
Innovent SG2501 bispecific antibody CD38/CD47 Hematological Malignancy Phase 1 single-drug therapy NCT05293912
IBI397 Monoclonal Antibody SIRPα IND IND
IBI188 Monoclonal Antibody CD47 Advanced Malignancies Phase 1 single-drug therapy

NCT03763149/

NCT03717103
IBI322 bispecific antibody CD47/PDL1 Advanced Malignancies Phase 1 single-drug therapy

NCT04338659/

NCT04328831
Solid Tumor Phase 1 single-drug therapy NCT04912466
Hematological Malignancy Phase 1 single-drug therapy NCT04795128
Myeloid Tumor Phase 1 HMA combination therapy NCT05148442
Haider Mahdi Pembrolizumab+ ALX148

blocking PD-1

and CD47

 CD47/PDL1 Ovarian Cancer Phase 2 Pembrolizumab+ ALX148 combination therapy NCT05467670
Baylor College of Medicine iC9-GD2 T Cells CAR-T GD2 Neuroblastoma Phase 1 iC9-GD2 T Cells/ Cytoxan/Fludara/Keytruda combination therapy NCT01822652

University Hospital Southampton

NHS Foundation Trust

 Ch14.18/CHO Monoclonal Antibody GD2 Neuroblastoma Phase 1 Nivolumab/Ch14.18/CHO NCT02914405
University of Wisconsin, Madison hu14.18-IL2

IL-2 linked to

hu14.18 mAb

 GD2 Melanoma Phase 2 hu14.18-IL2 combined with Nivolumab/ipilimumab combination therapy NCT03958383
JMT BIO JMT601 Fusion protein CD20/CD47 NHL Phase 1/2 single-drug therapy NCT04853329
Advanced Malignancies Phase 1 single-drug therapy

NCT03722186;

Suspended (Business Decision)
KAHR Medical DSP107 bispecific antibody CD47/41BB NSCLC Phase1/2 Atezolizumab

single-drug therapy and

combination therapy

 NCT04440735
Hematological Malignancies Phase1 Azacitidine/Venetoclax

single-drug therapy and

combination therapy

 NCT04937166
Lunan Pharmacy Monoclonal antibody CD47 Malignant tumor IND single-drug therapy /
MABWELL 6MW3211 Bispecific antibody CD47/PD-L1 Advanced Malignant Neoplasm Phase1/2 single-drug therapy NCT05048160
MAB WORKS MIL-95 Monoclonal antibody CD47 Advanced Malignancies Phase 1 single-drug therapy NCT04651348
OSE Immunotherapeutics OSE-172 Monoclonal antibody SIRPα Solid Tumor Phase1 BI 754091

single-drug therapy and

combination therapy

 NCT03990233
Advanced Cancer Phase 1 ezabenlimab/[89Zr]Zr- BI 765063 combination therapy NCT05068102
HNSCC Phase1

Ezabenlimab/BI 836880/Cetuximab/

Investigator´s Choice Chemotherapy

 combination therapy NCT05249426
Solid Tumor Phase1 BI 754091 single-drug therapy and combination therapy NCT04653142
Pfizer PF-07257876 bispecific antibody CD47/PDL1 Solid Tumor Phase 1 single-drug therapy NCT04881045
Seagen SGN-CD47M Antibody–Drug Conjugates CD47 Solid Tumor Phase 1 single-drug therapy NCT03957096
Shattuck Labs SL-172154 bispecific antibody SIRPα/CD40L SCC Phase 1 single-drug therapy NCT04502888
Sorrento Therapeutics STI-6643 Monoclonal Antibody CD47 Solid Tumor Phase 1 single-drug therapy NCT04900519
SUNHO (China) IBC0966 bispecific antibody CD47/PDL1 Advanced Malignancies Phase 1/2 single-drug therapy NCT04980690
Surface Oncology SRF231628,629 Monoclonal Antibody CD47 Solid Tumor/Hematological Malignancy Phase1 single-drug therapy NCT03512340
SUMGEN SG12473 bispecific antibody CD47/PD-1 Malignant tumor Phase 1 single-drug therapy CTR20211029
SG2501 bispecific antibody CD47/CD38 Hematological Malignancy Phase 1 single-drug therapy NCT05293912
SG404 Fusion protein CD47 Malignant tumor Phase 1 single-drug therapy CTR20202489
TG Therapeutics TG-1801 bispecific antibody CD47/CD19 Hematological Malignancy Phase 1 Biological: Ublituximab combination therapy NCT04806035
Trillium TTI-622 Fusion protein CD47 Solid Tumor Phase 1/2 Pegylated Liposomal Doxorubicin combination therapy NCT05261490
Leiomyosarcoma Phase 1/2 Doxorubicin combination therapy NCT04996004
Multiple Myeloma Phase 1 Daratumumab Hyaluronidase-fihj combination therapy NCT05139225
Hematological Malignancy Phase 1

Azacitidine/Venetoclax/Carfilzomib/Dexamethasone/

anti-CD20 targeting agent

single-drug therapy and

combination therapy

 NCT03530683
Solid Tumor Phase 1

Monotherapy/Drug: PD-1/PD-L1 Inhibitor/

pegylated interferon-α2a/Other:T-Vec/Other: radiation

 combination therapy NCT02890368
Advanced Malignancies Phase 1 Drug: Rituximab/Drug: Nivolumab combination therapy NCT02663518
Trillium Therapeutics TT1-621 Fusion protein CD47 Leiomyosarcoma Phase 1/2 Doxorubicin combination therapy NCT04996004
Solid Tumor/Hematological Malignancy Phase1 Rituximab/Drug: Nivolumab

single-drug therapy and

combination therapy

 NCT02663518
Solid Tumor Phase1

PD-1/PD-L1 Inhibitor/pegylated interferon-α2a

/T-Vec/radiation

 single-drug therapy and combination therapy NCT02890368
Waterstone HX009 bispecific antibody CD47/PD1 Lymphoma Phase 2 single-drug therapy NCT05189093
Solid Tumor Phase 1/2 single-drug therapy

NCT04886271/

NCT04097769
ZAI LAB ZL-1201 Monoclonal Antibody CD47 Advanced Cancer Phase 1 single-drug therapy NCT04257617
Celgene Corporation Anti-SIRPα CC-95251 SIRPα Advanced Solid and Hematologic Cancers Phase1 Cetuximab, Rituximab

Alone and in Combination with Cetuximab

or Rituximab

 NCT03783403
Celgene CC-90002 Monoclonal Antibody CD47 AML/MDS Phase1 single-drug therapy NCT02641002
Insilico Medicine ISM004-1057D targeting pyroglutamylation of CD47 CD47 (isoQC) Solid Tumor/Hematological Malignancy IND IND
Nantes University Hospital Monoclonal Antibody SIRPα HCC Phase 1 single-drug therapy

NCT02868255

completed in Sep.2021
Shandong New Time Pharmaceutical F527 Monoclonal Antibody CD47 Lymphoma Phase 1 single-drug therapy NCT05293028
SUNHO IBC0966 bispecific antibody CD47/PDL1 Advanced Malignant Tumors Phase 2 single-drug therapy NCT04980690
Gilead Sciences(Bought Forty Seven in 2020) Magrolimab (Hu5F9 G4) Monoclonal Antibody CD47 Myelodysplastic Syndromes Phase 3 Azacitidine/Placebo combination therapy NCT04313881
AML Phase 3 Venetoclax/Azacitidine combination therapy NCT05079230
AML Phase 3 Azacitidine combination therapy NCT04778397
Hodgkin Lymphoma Phase 2 Pembrolizumab combination therapy NCT04788043
Solid Tumors Phase 2 Docetaxel combination therapy NCT04827576
Metastatic Colorectal Cancer Phase 2 Bevacizumab/Irinotecan/Fluorouracil/Leucovorin combination therapy NCT05330429
Triple-Negative Breast Cancer Phase 2 Nab-Paclitaxel/Paclitaxel/Sacituzumab govitecan combination therapy NCT04958785
Multiple Myeloma Phase 2

Daratumumab/Pomalidomide/Dexamethasone/

Bortezomib/Carfilzomib

 combination therapy NCT04892446
Head and Neck Squamous Cell Carcinoma Phase 2 pembrolizumab/5-FU/platinum/docetaxel combination therapy NCT04854499
Myeloid Malignancies Phase 2

venetoclax/azacitidine /mitoxantrone/etoposide/

cytarabine/CC-486

 combination therapy NCT04778410
Solid Tumor Phase 1/2 Cetuximab combination therapy

NCT02953782

finished in Mar.2021
Non Hodgkin Lymphoma Phase 1/2 rituximab/gemcitabine/oxaliplatin combination therapy NCT02953509
AML Phase 1/2 Azacitidine/Venetoclax combination therapy NCT04435691
Urothelial Carcinoma Phase 1/2 Atezolizumab combination therapy NCT03869190
MDS/AML Phase 1/2 Sabatolimab/Azacitidine combination therapy NCT05367401
T-Cell Lymphoma Phase 1/2 mogamulizumab combination therapy

NCT04541017;

Suspended (Other - Amendment Request)
B-cell Malignancies Phase 1 Obinutuzumab/Venetoclax combination therapy NCT04599634
Hematological Malignancies Phase 1 Azacitidine combination therapy NCT03248479
AML Phase 1 Atezolizumab combination therapy NCT03922477
Ovarian Cancer Phase 1 Avelumab combination therapy

NCT03558139

Completed in Dec.2020
Non-Hodgkin’s Lymphoma Phase 1 Acalabrutinib/AZD6738/Rituximab/AZD5153 combination therapy NCT03527147
Neuroblastoma/Osteosarcoma Phase 1 Dinutuximab/ combination therapy NCT04751383
MDS/AML Phase 1 single-drug therapy NCT02678338
Solid Tumor Phase 1 single-drug therapy NCT02216409
Brain Tumors Phase 1 single-drug therapy NCT05169944

Shenzhen Geno-Immune

Medical Institute

 Sarcoma-specific CAR-T cells CAR-T GD2 Sarcoma, Osteoid Sarcoma, Ewing Sarcoma Phase 2 single-drug therapy NCT03356782
Xuanwu Hospital, Beijing GD2-CAR-T cells CAR-T GD2 Glioma,Malignant Glioma of Brain,Recurrence Tumor Phase 1 single-drug therapy NCT03423992
Biond Biologics BND-22 Monoclonal Antibody LILRB1 Advanced Solid Tumors Phase 1/2 Pembrolizumab combination therapy NCT04717375
Advanced Solid Tumors Phase 1/2 Cetuximab combination therapy NCT04717375
Advanced Solid Tumors Phase 1/3 Alone NCT04717375
NGM Biopharmaceuticals, Inc NGM707 Dual antibody LILRB1/LILRB2 Advanced or Metastatic Solid Tumor Malignancies Phase 1/2 Alone NCT04913337
Phase 1/3 pembrolizumab combination therapy NCT04913337
Tizona Therapeutics TTX-080 Monoclonal Antibody HLA-G advanced refractory / resistant solid malignancies Phase 1 Alone NCT04485013
Phase 1 pembrolizumab combination therapy NCT04485013
Phase 1 cetuximab combination therapy NCT04485013
Janssen Research & Development, JNJ-78306358

Bispecific antibody binding to CD3 on

T cells and human leukocyte antigen G (HLA-G) on cancer cells

 HLA-G Advanced Stage Solid Tumors Phase 1 single-drug therapy NCT04991740
Tianhong Li CD24Fc CD24 Extracellular Domain-IgG1 Fc Domain Recombinant Fusion Protein CD24Fc CD24 solid tumors Phase 1/2 single-drug therapy NCT04552704(Terminated early by the Sponsor due to the sponsor change.)
OncoImmune, Inc. CD24Fc CD24 Extracellular Domain-IgG1 Fc Domain Recombinant Fusion Protein CD24Fc CD24 Metastatic Melanoma phase Ib/II Ipilimumab combination therapy NCT04060407 Withdrawn (Business Reasons)
Nivolumab combination therapy
OncoImmune, Inc CD24Fc CD24 Extracellular Domain-IgG1 Fc Domain Recombinant Fusion Protein CD24Fc CD24 Acute Myeloid Leukemia Phase 3 Methotrexate combination therapy NCT04095858 Withdrawn (Business Reasons)
Acute Lymphoblastic Leukemia Tacrolimus combination therapy
Myelodysplastic Syndrome single-drug therapy
Hematopoietic Stem Cell Transplantation Placebo
Acute Graft Versus Host Disease
Tel-Aviv Sourasky Medical Center EXO-CD24 CD24 SARS-CoV-2 Phase 1 single-drug therapy NCT04747574
Athens Medical Society EXO-CD24 CD24 Covid19 Phase 2 single-drug therapy NCT04902183
Eli Sprecher, MD Exosomes overexpressing CD24 CD24 COVID-19 Disease Phase 2 single-drug therapy NCT04969172
OncoImmune, Inc. CD24Fc CD24 Coronavirus Disease 2019 (COVID-19) Phase 3 single-drug therapy NCT04317040